Recombinant Human Interleukin-6 as a Treatment for Demyelinating Disease (Multiple Sclerosis)

Reference #:

1994-112

Inventors/Contributors

Moses Rodriguez, M.D.

Description

Researchers utilize a murine model of multiple sclerosis induced by Theiler's virus to test the effect of interleukin-6 on central nerous system demyelination. Administration of human recombinant interleukin-6 dramatically reduced demyelination and inflammation in the spinal cord of susceptible SJL mice. These studies in an animal model of multiple sclerosis suggest that this interleukin may have application for the treatment of human multiple sclerosis.

Patent Status

	U.S. Patent Number 5,863,529 Issued January 26, 1999